Changes to the Board of directors

At the Extraordinary General Meeting of 2cureX AB (publ) today, 29 February 2024, it was decided to elect Grith Hagel as a new board member.

This election a part of a strategic initiative as 2cureX refines its strategy to facilitate the implementation of IndiTreat® testing across individual hospitals. Such a move towards decentralization necessitates an enhancement of the company's expertise in technical and regulatory areas. Grith Hagel is poised to significantly contribute to the integration and adoption of the IndiTreat® platform within cancer hospitals due to her background and expertise.

As a co-founder of 2cureX and previously of BioImage, a company that evolved from Novo Nordisk, where she had a pivotal role in establishing and managing a highly profitable partnership between BioImage and Amersham plc (presently GE Healthcare) showcases her capabilities. Moreover, Grith's contributions as an inventor with a comprehensive portfolio of issued patents, particularly those that offer substantial intellectual property protection for IndiTreat® in key global markets, underline her valuable asset to the company.

The Board of Directors hereafter consists of Tonny Bülow-Nielsen, Grith Hagel and Ole Thastrup.

Publication

The information was submitted for publication, through the agency of the contact persons set out below, at 16:00 CEST on February 29, 2024.

Malmö in February 2024

2cureX AB (publ)

Board of Directors

N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the extraordinary general meeting in 2cureX AB, and in case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.